Literature DB >> 28795842

Recommendations for Pathologic Evaluation of Reduction Mammoplasty Specimens: A Prospective Study With Systematic Tissue Sampling.

Abiy B Ambaye1, Andrew J Goodwin1, Susan E MacLennan1, Shelly Naud1, Donald L Weaver1.   

Abstract

CONTEXT: - Breast reduction mammaplasty (RMP) for symptomatic macromastia or correction of asymmetry is performed in more than 100 000 patients per year in the United States. The reported incidence of significant pathologic findings (SPF), that is, carcinoma and atypical hyperplasia, ranges from 0.06% to 12.8%. No standard pathology assessment for RMP exists.
OBJECTIVES: - To propose standard sampling for microscopic evaluation in RMP specimens, to evaluate the incidence of occult carcinoma and atypical hyperplasia, and to identify clinical risk factors for SPF in patients undergoing RMP.
DESIGN: - All RMP specimens from 2006 to 2013 at a single institution were prospectively examined. After baseline gross and microscopic evaluations, each specimen was subjected to systematic additional sampling. The incidence of SPF was tabulated, and variables such as age, specimen weight, previous history of SPF, and results of preoperative mammogram were examined. Clinical follow-up review was also subsequently undertaken.
RESULTS: - A total of 595 patients were evaluated. Significant pathologic findings were present in 9.8% (58 of 595) of patients. No cancer was identified in patients younger than 40 years; the rates of carcinoma were 2.4% (14 of 595) in all patients, 3.6% (14 of 392) in patients aged 40 years or older, and 4.3% (10 of 233) in patients aged 50 years or older. No carcinoma or atypical hyperplasia was identified on preoperative mammogram. Increased sampling was associated with a significantly greater frequency of SPF only in patients aged 40 years or older.
CONCLUSIONS: - In patients younger than 35 years, gross-only evaluation is sufficient. However, increased sampling may be necessary in patients older than 40 years.

Entities:  

Mesh:

Year:  2017        PMID: 28795842     DOI: 10.5858/arpa.2016-0492-OA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  4 in total

1.  Pathology Evaluation of Reduction Mammaplasty Specimens and Subsequent Diagnosis of Malignant Breast Disease: A Claims-Based Analysis.

Authors:  Erika D Sears; Yu-Ting Lu; Ting-Ting Chung; Adeyiza O Momoh; Kevin C Chung
Journal:  World J Surg       Date:  2019-06       Impact factor: 3.352

2.  Pathology Examination of Breast Reduction Specimens: Dispelling the Myth.

Authors:  Mark Fisher; Aaron L Burshtein; Joshua G Burshtein; Panagiotis Manolas; Scot B Glasberg
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-11-24

3.  The Safety, Cosmetic Outcome, and Patient Satisfaction after Inferior Pedicle Reduction Mammaplasty for Significant Macromastia.

Authors:  Muna M Baslaim; Shefaa Ahmed Al-Amoudi; Mohammed Hafiz; Wedyan Mohammed Al-Hazmi; Budoor Ahmed Salman; Mohammed Khalid Al-Amoudi
Journal:  Plast Reconstr Surg Glob Open       Date:  2018-06-19

4.  Discussion of Histopathological Findings of 954 Breast Reduction Specimens.

Authors:  Soysal Bas; Cagatay Oner; Ali Can Aydin; Ramazan Ucak; Selami Serhat Sirvan; Semra Karsidag
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2021-03-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.